Replies to post #162085 on Biotech Values

[exwannabe]

I do not follow PPHM but I took a brief look at their NSCLC presentation.

One thing attracted my attention. There are many more Asian pts in Bavi-arm vs Combined-Placebo-arm

FWI, the posted HR was a cox regression which included stage, histiology and number of organs with mets.

[sarcasm]I am certain that race was plugged into the equation but was not a major factor[/sarcasm].

[north40000]

How many, if any, patients in either arm are still alive?

What is the ethnic background of the deceased patients in each arm?

What is the ethnic background of the still living patients, if any, in each arm?

I assume you would need to know the answers to those questions to make or validate your point.

[freethemice]

Asian patients, as in Japanese and Chinese, do live longer. But, these were from India, AND you can see on the
subgroup analysis table that the Asian subgroup had a higher HR number (closer to 1) than the European and
United States patients. If the Asian patients were a factor then their HR number would be smaller, not larger.
In other words, bavi + docetaxel was of more benefit to the US and European patients than to the Asian patients,
contrary to your claim.